Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system

Fig. 3

Progression-free survival (PFS) and overall survival (OS) of patients with PCNS-DLBCL according to combined MYC and BCL2 expression status. a and b PFS and OS of patients without expression for either MYC or BCL2 (double-negative) versus other groups are plotted using the Kaplan-Meier method and analyzed by the log-rank test. c and d PFS and OS of patients with concomitant MYC and BCL2 expression (double-positive) versus other groups are plotted using the Kaplan-Meier method and analyzed by the log-rank test. e and f PFS and OS of patients treated with combined MVP and radiotherapy according to the MYC and BCL2 expression status were plotted using the Kaplan-Meier method and analyzed by the log-rank test

Back to article page